EGFR and non-small cell lung carcinoma: According to a cohort analysis of the CHRYSALIS trial presented at the American Society of Clinical Oncology (ASCO) 2021 virtual annual meeting, dual EGFR targeting with amivantamab-vmjw (Rybrevant) plus lazertinib (Leclaza) led to durable responses in more than one-third of chemotherapy-naive patients with EGFR-positive non-small-cell lung cancer (NSCLC) whose disease had progressed on osimertinib (23).